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Abstract
Background: The present study evaluates the outcome of 19 children with rhabdomyosarcoma
of the head-and-neck region treated with Intensity Modulated Radiotherapy (IMRT) or
Fractionated Stereotactic Radiotherapy (FSRT) between August 1995 and November 2005.
Methods: We treated 19 children with head-and-neck rhabdomyosarcoma with FSRT (n = 14) or
IMRT (n = 5) as a part of multimodal therapy. Median age at the time of radiation therapy was 5
years (range 2–15 years). All children received systemic chemotherapy according to the German
Soft Tissue Sarcoma Study protocols.
Median size of treatment volume for RT was 93,4 ml. We applied a median total dose of 45 Gy
(range 32 Gy – 54 Gy) using a median fractionation of 5 × 1,8 Gy/week (range 1,6 Gy – 1,8 Gy).
The median time interval between primary diagnosis and radiation therapy was 5 months (range 3–
9 months).
Results: After RT, the 3- and 5-year survival rate was 94%. The 3- and 5-year actuarial local control
rate after RT was 89%.
The actuarial freedom of distant metastases rate at 3- and 5-years was 89% for all patients.
Radiotherapy was well tolerated in all children and could be completed without interruptions > 4
days. No toxicities >CTC grade 2 were observed. The median follow-up time after RT was 17
months.
Conclusion: IMRT and FSRT lead to excellent outcome in children with head-and-neck RMS with
a low incidence of treatment-related side effects.
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Background
Rhabdomyosarcoma (RMS) is the most common soft tis-
sue sarcoma entity in children [1]. The most common
sites of RMS in children are the head and neck region
(35%), the genitourinary tract (35%) and the extremities
(17%) [2]. The orbit is the primary site in about 10% of
these tumors, the most common localization in the head
and neck area is parameningeal, including the nasophar-
ynx, the paranasal sinuses, the middle ear and mastoid
and the infratemporal fossa/pterygopalatine space [2-8].
Most children are younger than 10 years of age (72%) [9].
Modern therapy protocols comprise of surgical resection,
chemotherapy and radiotherapy (RT). However, RT in
children is commonly applied cautiously with respect to
early and late side effects [10-14].
With modern RT techniques such as Intensity Modulated
Radiotherapy (IMRT) and Fractionated Stereotactic Radi-
otherapy (FSRT), the treatment of complex shaped target
volumes in close vicinity to sensitive risk structures is pos-
sible [15-17]. The present study evaluates the efficacy and
toxicity FSRT and IMRT in children with head and neck
RMS.
Methods
From August 1995 to November 2005, we treated 19 chil-
dren with RMS of the head-and-neck region with FSRT (n
= 14) and IMRT (n = 5) at our institution.
The data presented in this analysis were acquired retro-
spectively and anonymously; therefore, no official
approval by the local ethics committee was necessary.
Patients' characteristics
The distribution of the tumor sites is shown in table 1. The
median age of the children was 5 years at the time of RT
(range 2–15 years). The male to female ratio was 1,4 : 1.
Before radiation therapy, all patients had undergone at
least one surgical procedure. At primary diagnosis, 3
patients had a subtotal tumor resection, and in 16 patients
only a biopsy was performed.
Patients were classified according to the surgical-patho-
logic grouping system used in the Intergroup Rhabdomy-
osarcoma Study Group (IRSG) trials [18,19]. The patients'
characteristics can be found in table 1.
All patients included into this study received systemic
chemotherapy according to the German Soft Tissue Sar-
coma Study protocols CWS 91, CWS 96 and CWS 2002
[20,21]. The aggressive interdisciplinary treatment con-
cepts are performed in close collaboration between the
radiation oncologist and the pediatric oncologist. All
patients were registered at the CWS study center.
The median time interval between primary diagnosis and
radiation therapy was 5 months (range 3–9 months).
Treatment planning for FSRT and IMRT
Patients were immobilized using an individual mask fixa-
tion system made of Scotch-Cast™; for treatment planning
contrast-enhanced MRI- and CT-scans were acquired with
the mask attached to a non-invasive stereotactic localiza-
tion frame with an overall geometrical uncertainty of 1–2
mm [22].
For FSRT, we used the three-dimensional treatment plan-
ning system Voxelplan [23]. Three to five isocentric non-
coplanar irregularly shaped fields formed by a midsize
multileaf collimator were applied.
For IMRT, the inverse treatment-planning program Kon-
rad (MRC Systems GmbH, Heidelberg, Germany) was
used [24,25]. An integrated multi-leaf collimator allowed
for IMRT using the "step-and-shoot" technique described
previously [26]. Fig. 1 shows an IMRT treatment plan for
a child with head and neck RMS.
Median size of the planning target volume (PTV) for radi-
ation was 93,4 ml (range 20,8 – 354,8 ml), consisting of
the area of contrast uptake in T1-weighted sequences and
Table 1: Patients' characteristics of 19 children with primary 
head-and-neck rhabdomyosarcoma treated with FSRT or IMRT
Site n (%)
Orbit (only) 5 (26)
Parameningeal 12 (63)
Orbit 3
Middle ear/mastoid 3
Nasopharynx/nasal cavity 6
Paranasal sinus 3
Pterygopalatine/parapharyngeal
and infratempotal fossa
4
Other head and neck 2 (11)
Buccal space 1
Lip and cheek 1
Histology
embryonal 12 (63)
alveolar 3 (16)
botryoid 4 (21)
IRS-Group
III 17(89)
IV 2 (11)
CWS Study Protocol
CWS 91 1 (5)
CWS 96 7 (37)
CWS 2002 11 (58)BMC Cancer 2007, 7:177 http://www.biomedcentral.com/1471-2407/7/177
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the enhancing lesion and edema visible in T2-weighted
MRI scans prior to chemotherapy including a 20 mm
safety margin. It was our policy to define the PTV accord-
ing to the common guidelines outlined in the treatment
protocols of the GPOH. Gross tumor volume (GTV) and
clinical target volume (CTV) were not defined separately
for planning purposes.
We applied a median total dose of 45 Gy (range 32 Gy –
54 Gy) using a median fractionation of 5 × 1,8 Gy/week
(range 1,6 Gy – 1,8 Gy).
In 4 patients, the total dose was applied in a hyperfrac-
tionated regimen using single fraction doses of 1,6 Gy.
Deep sedation or general anaesthesia was required in 5
out of 19 children.
Follow-up
Patients were seen for follow-up 6 weeks after radiation,
thereafter in 3 to 12 months intervals, including contrast-
enhanced MRI-scans, anamnesis and clinical examina-
tion. The clinical oncological follow-up was performed by
the attending pediatric oncologist. Median follow-up time
was 17 months (range 3 months 12 years).
Statistics
Overall survival was calculated from primary diagnosis,
survival after RT was calculated from initiation of RT. Pro-
gression-free survival after RT was calculated from the first
day of RT until tumor progression (local or distant) or
death (by any cause), whichever happened first, using the
Kaplan Meier method [27]. All statistical analyses were
performed using the Statistica 6.1 Software (StatSoft,
Tulsa, OK, USA).
Results
Survival
Overall survival rate after primary diagnosis of the RMS
was 94% at 3 and 5 years, respectively (Fig. 2). One
patient died of tumor progression.
Local control
The 3- and 5 year actuarial local control rate after RT was
89% (Fig. 3A). We observed 2 local recurrences.
Overall survival in 19 children with head-and-neck RMS  treated with FSRT or IMRT Figure 2
Overall survival in 19 children with head-and-neck RMS 
treated with FSRT or IMRT.
Typical 3D treatment plan of Intensity modulated Radiotherapy (IMRT) for a child with head-and-neck RMS Figure 1
Typical 3D treatment plan of Intensity modulated Radiotherapy (IMRT) for a child with head-and-neck RMS. Thick red line = 
target volume; orange area 90–100% of the total dose; yellow area 70–90% of the total dose; green area 50–70% of the total 
dose; blue areas 10–50% of the total dose.BMC Cancer 2007, 7:177 http://www.biomedcentral.com/1471-2407/7/177
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With respect to tumor localization, the 3- and 5-year local
control rates were 100% for patients with RMS of the orbit
and 91% for patients with parameningeal tumors. One
patient with parameningeal RMS developed local progres-
sion within the prior RT field of the tumor after 4 months.
The patient had received a total RT dose of 54 Gy, RT was
initiated 5 months after primary diagnosis after inclusion
into the CWS-91 protocol. The tumor had shown no
response to the CWS chemotherapy (ifosfamide, vincris-
tine, actinomycin-D), and the chemotherapy regimen was
switched to carboplatin/etoposide, which showed also no
response. Thereafter, RT was initated.
One patient with RMS (ISG Group 4) of the mylohyoid
muscle developed local failure 2 months after completion
of RT simultaneously with distant bone metastases and
progression of the lung metastases present at primary
diagnosis. This patient was 1 year old at primary diagno-
sis, was included into the CWS 2002 protocol and showed
no response to chemotherapy prior to RT, which was ini-
tiated 4 months after diagnosis; a total RT dose of 54 Gy
was applied. At primary diagnosis, lung metastases were
already present.
The rate of local control in children with parameningeal
and head- and-neck tumors was 81% at 3- and 5-years as
compared to 100% in RMS involving the orbit only (Fig.
3B).
Distant metastases-free survival
The actuarial freedom of distant metastases rate at 3- and
5-years was 89% for all patients at 3 and 5 years (Fig. 3C).
For patients with RMS of the orbit only, the actuarial dis-
tant progression-free rate was 100% at 5 year. One patient
with parameningeal RMS developed distant metastases in
both lungs 6 months after completion of RT and 1 month
Local Control rates were 89% after 3- and 5-years (A) Figure 3
Local Control rates were 89% after 3- and 5-years (A). For RMS of the orbit only, local control was 100% after 5 years, and 
81% for parameningeal RMS and other RMS of the head and neck (B). The rate of distant metastases-free survival was 89% at 5 
years (C). Distant-metastases free survival rates were 100% for orbital RMS, and 81% for parameningeal and other head-and-
neck RMS (D).BMC Cancer 2007, 7:177 http://www.biomedcentral.com/1471-2407/7/177
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after local tumor progression. The actuarial 3- and 5-year
distant disease-free survival rate was 91%, respectively in
children with parameningeal RMS. As noted above, one
girl diagnosed with ISRG 4 RMS of the mylohyoid muscle
developed local and distant progression simultaneously 2
months after completion of RT. The rate of distant-metas-
tases-free survival in children with parameningeal and
head-and -neck RMS was 81% at 5-years as compared to
100% in children with involvement of the orbit only (Fig.
3D).
Toxicity
Radiotherapy was well tolerated in all children and could
be completed without interruptions > 4 days.
Acute radiation induced toxicity
Minor acute radiation-induced side effects occurring
within 3 months from RT included skin erythema in 8
patients (42%), alopecia in 4 patients (21%), conjunctivi-
tis in 3 patients (16%), mucositis in 8 patients (42%) and
nausea/vomiting in 2 patients (11%); no toxicities >CTC
grade 2 developed.
Long-term radiation induced toxicity
To date, the long-term toxicity, developing per definition
<6 months after RT, developed in 9 out of 19 patients
(47%). We observed three patients with reduced lacrima-
tion and one patient with chronic swelling of the left eye
lid with slight erythema CTC grade 1. One patient devel-
oped trismus. However, the poor cooperation of the
patient in training mouth opening after RT could have
contributed to this outcome. In one patient growth hor-
mone deficiency developed with subsequent microsomia
requiring growth hormone replacement. This patient had
been treated with the initial CWS-96 protocol followed by
treatment according to the CWS-protocol for tumor recur-
rence. Radiotherapy had been applied during the initial
protocol with 32 Gy, followed by 8 Gy brachytherapy and
50,4 Gy FSRT for tumor recurrence. In one patient with
orbital RMS visual deficiency present prior to RT declined
leading to amaurosis. Optic pathway structures received a
dose of 34 Gy in 1,8 Gy fractions. Discrete erythema and
swelling of the eye lid was observed in the same patient
with reduced lacrimation. One patient presented with
reduced mouth-opening, and facial asymmetry developed
in one patient only (5%). One patient with RMS of the
pterygoid fossa developed asymmetric growth of the face
with growth reduction on the left side. Until now, no sec-
ondary malignancies developed.
Discussion
Treatment guidelines of RMS include surgical resection,
systemic chemotherapy using combinations of actinomy-
cin-D, vincristine and cyclophosphamide as well as RT.
Commonly, children with RMS are treated within inter-
disciplinary study protocols: the IRSG (North America),
SIOP (Europe), CWS (Germany) and ICS protocols (Italy)
[28]. Radiation therapy is an essential part in all treatment
protocols for all but completely resected low risk tumors
[29,30]; as a result of these multimodality approaches, the
prognosis for children with RMS has improved, with long-
term survival rates of 70–80%.
While improvement of outcome with respect to local and
distant failures, radiation-induced side effects remained a
major problem [31].
IMRT and FSRT enable the delivery of high doses to a
defined target volume while sparing surrounding organs
at risk; especially for complex shaped tumors of the head-
and-neck, RT doses required can be applied while adher-
ing to the tolerance doses of critical normal tissue struc-
tures. FSRT has been used safely and effectively for other
childhood tumors [32,33]. IMRT helps spare normal tis-
sues from high-dose areas, but delivers low doses to larger
volumes of normal tissue discussed critically with respect
to the risk of secondary malignancies. We reserved IMRT
for cases in which FSRT did not yield acceptable dose dis-
tributions taking into account commonly accepted physi-
cal parameters like 90% target coverage and maximum/
minimum doses to the adjacent organs at risk.
FSRT and IMRT were chosen in order to reduce dose to
normal tissue structures as a general philosophy, but tar-
get volumes were not altered with different treatment
techniques. Great effort was made to choose beam angles
in order to reduce irradiation of bony structures not
included into the target volumes in growing children. In
patients where bony structures had to be included, e.g.
cervical spine, symmetrical irradiation was ensured in
order to avoid asymmetric bone growth whenever possi-
ble without compromises in target coverage and without
exceeding the tolerance dose of normal tissue structures.
During follow-up, only one patient with RMS of the ptery-
goid fossa developed asymmetric growth of the face with
growth reduction on the left side. It must be noted that
observation time after RT is relatively short to fully deter-
mine long-term side effects such as cosmetic deformity.
Therefore, longer follow-up time is needed to make final
statements.
With the steep dose-fall off generated by modern high-
precision RT, some concern has been raised as to whether
the risk of tumor recurrences at the field border might be
increased. The results obtained in the present analysis
compare favourably to the results published by the large
pediatric hematology study groups and reports on single-
institution studies [1,34-38]. Using FSRT and IMRT, theBMC Cancer 2007, 7:177 http://www.biomedcentral.com/1471-2407/7/177
Page 6 of 7
(page number not for citation purposes)
rate of field-border recurrences seems not to be increased
outside the PTV as long as the PTV itself is not reduced.
A study published by Wolden et al. reported on 28
patients with head-and-neck RMS [39]. Patients with alve-
olar histologic features showed significantly worse out-
comes as compared to embryonal or undifferentiated
tumors. However, in our study, histology as well as other
established prognostic factors showed no statistically sig-
nificant influence on the outcome, most probably due to
the small patient number and the small number of events.
Furthermore, these factors have already been addressed by
the CWS trials which follow a risk-adapted combination
of CHT and RT.
Proton RT is another treatment modality enabling the
application of high doses while sparing surrounding nor-
mal tissue. Preliminary results of proton RT in children
with orbital RMS were published by Yock et al. [40]. At the
MGH in Boston, 7 children with orbital RMS were treated
with proton irradiation in combination with standard
chemotherapy. Treatment plan intercomparisons of pro-
ton plans and conventional 3-D plans showed that with
proton RT excellent tumor coverage can be obtained while
reducing the radiation dose to the adjacent normal tis-
sues.
Conclusion
FSRT and IMRT offer excellent results for the treatment of
pediatric patients with RMS of the head-and-neck region.
The incidence of acute and long-term side-effects is very
low. Since only few centers can offer the treatment of pedi-
atric patients with protons to date, FSRT and IMRT can be
considered the best photon therapy modalities for a
number of pediatric patients with head-and-neck RMS
[40].
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